GSK Earnings & Financial Statements
GSK plc
$45.88
-$1.14(-2.42%)
30
Overall
--
Value
40
Tech
21
Quality
Market Cap
$94.06B
Volume
2.98M
52W Range
$42.85 - $61.70
Target Price
$58.17
GSK earnings and financial statements: GSK plc's income statement, balance sheet and cash flow statement, annual and quarterly.
GSK Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $32.67B | $31.38B | $30.33B | $29.32B | $34.11B |
| Cost of revenue | $9.02B | $9.05B | $8.56B | $9.55B | $8.16B |
| Operating income | $7.05B | $7.08B | $6.75B | $5.67B | $6.68B |
| EBITDA | $7.40B | $7.21B | $6.85B | $8.60B | $6.49B |
| Net income | $5.72B | $5.64B | $4.93B | $14.96B | $4.38B |
| EPS (diluted) | - | $0.62 | $1.20 | $3.66 | $1.35 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $61.12B | $59.46B | $59.01B | $60.15B | $79.10B |
| Total liabilities | $45.16B | $46.38B | $46.21B | $50.05B | $57.76B |
| Shareholders’ equity | $16.38B | $13.67B | $13.35B | $10.60B | $15.05B |
| Cash and equivalents | $3.40B | $3.87B | $2.94B | $3.72B | $4.07B |
| Long-term debt | $14.71B | $14.64B | $15.21B | $17.04B | $20.57B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $7.74B | $6.55B | $6.77B | $7.40B | $7.95B |
| Free cash flow | $6.10B | $3.57B | $4.42B | $5.14B | $7.95B |
| Dividends paid | $2.96B | $2.86B | $2.25B | $3.47B | $4.00B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GSK | $45.88 | -2.4% | 2.98M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |